SCHEMBL23948506

SCHEMBL23948506

NCCCCCC(=O)NCCC1=CC=CCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
SLC6A5 Q9Y345 2/20 0.39
HDAC3 O15379 4/20 0.38
HDAC1 Q13547 4/20 0.38
HDAC2 Q92769 4/20 0.38
HDAC10 Q969S8 4/20 0.38
HDAC11 Q96DB2 4/20 0.38
HDAC8 Q9BY41 4/20 0.38
HDAC6 Q9UBN7 4/20 0.38
NCOR2 Q9Y618 1/20 0.38
CYP3A4 P08684 1/20 0.37
MMP2 P08253 1/20 0.37
HPGD P15428 2/20 0.36
F13A1 P00488 1/20 0.35
HDAC4 P56524 3/20 0.35
HDAC7 Q8WUI4 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25827828 0.87 TRPV1 (0.48) MEN1KMT2AHSD17B10
SCHEMBL20825036 0.77 MTNR1A (0.36) ALDH1A1HPGD
SCHEMBL23948508 0.72 CA1 (0.40) ALDH1A1MEN1KMT2ACA1CA2
SCHEMBL17039863 0.71 SLC6A5 (0.59) ALDH1A1MEN1KMT2ASLC6A5CYP3A4
SCHEMBL7215946 0.69 SLC6A5 (0.67) ALDH1A1MEN1KMT2ASLC6A5
SCHEMBL7203302 0.69 SLC6A5 (0.67) ALDH1A1MEN1KMT2ASLC6A5
SCHEMBL7209833 0.69 SLC6A5 (0.67) ALDH1A1MEN1KMT2ASLC6A5
SCHEMBL7208464 0.69 SLC6A5 (0.67) ALDH1A1MEN1KMT2ASLC6A5
SCHEMBL22289072 0.69 SLC6A5 (0.57) ALDH1A1MEN1KMT2ASLC6A5CYP3A4
SCHEMBL7215984 0.69 SLC6A5 (0.67) ALDH1A1MEN1KMT2ASLC6A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207412-A1 DIELS-ALDER CONJUGATION METHODS REGENERON PHARMACEUTICALS, INC. (US) 2024-06-27 US disclosed
US-20240207412-A1 DIELS-ALDER CONJUGATION METHODS REGENERON PHARMACEUTICALS, INC. (US) 2024-06-27 US disclosed
US-11701427-B2 Diels-alder conjugation methods REGENERON PHARMACEUTICALS, INC. (US) 2023-07-18 US disclosed
US-11701427-B2 Diels-alder conjugation methods REGENERON PHARMACEUTICALS, INC. (US) 2023-07-18 US disclosed
WO-2021211984-A1 DIELS-ALDER CONJUGATION METHODS REGENERON PHARMACEUTICALS, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207412-A1 DIELS-ALDER CONJUGATION METHODS GLUL, TGM2, GLS ALDH1A1 74/4885MEN1 613/4885KMT2A 1013/4885
US-11701427-B2 Diels-alder conjugation methods GLUL, TGM2, GLS ALDH1A1 74/4885MEN1 613/4885KMT2A 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.